As shown in Fig. 1C, the rate of MAP4K4 overexpression did not appear to vary among tumors with EGFR mutations (25/32, 78% with MAP4K4 overexpression), KRAS mutations (45/69, 65% with MAP4K4 overexpression), or neither mutation (21/35, 60% with MAP4K4 overexpression), implying that MAP4K4 elevation in lung adenocarcinoma is not associated with KRAS or EGFR mutation, hence excluding mutant KRAS or mutant EGFR as causes for MAP4K4 dysregulation. This evidence concerns the gene KRAS and lung adenocarcinoma.